Atezolizumab-Bevacizumab Immunotherapy Breakthrough: Transforming Liver Cancer Treatment in India

▴ Atezolizumab-Bevacizumab
Indian study: Atezolizumab-Bevacizumab combo in uHCC shows promising results, with tumour shrinkage and survival benefits, especially when coupled with early treatment and local radiation therapy.

In a groundbreaking study conducted by the Asian Institute of Gastroenterology (AIG), a promising breakthrough in liver cancer treatment has been unveiled, heralding renewed hope for patients grappling with this formidable disease. The study focused on utilizing the potential of Atezolizumab-Bevacizumab immunotherapy, harnessing the body's immune system to combat cancer cells effectively.

Atezolizumab-Bevacizumab, an immunotherapeutic combination, has demonstrated substantial success in managing unresectable hepatocellular carcinoma (uHCC) in real-world settings. The study involved 67 patients with uHCC, comprising 59 individuals from AIG Hospital, Hyderabad, and 8 from Mahatma Gandhi Medical College, Jaipur. The median age of the patients receiving this combination therapy was 61 years, with a majority being males.

The results of the study are indeed promising. Researchers reported that 12.9 per cent of patients achieved complete resolution of tumours, while 25.8 per cent experienced partial resolution or shrinking of tumours. Furthermore, the disease progression halted in an impressive 66.12 per cent of the patients under examination.

In patients with well-functioning livers, the overall survival span reached an encouraging 21 months. Given that liver cancer is often diagnosed at advanced stages, this breakthrough treatment offers a glimmer of hope for improved survival rates, especially when administered to patients with optimal liver function.

An intriguing finding of the study was the enhanced response rates observed in patients who had undergone local radiation therapy in addition to the Atezolizumab-Bevacizumab combination. This suggests the heightened efficacy of this immunotherapeutic pairing in conjunction with localized radiation treatment.

Dr. Nageshwar Reddy, Chairman and Chief of Gastroenterology at AIG Hospitals, emphasized how liver cancer's dynamics are shifting from hepatitis B as a primary cause to non-alcoholic steatohepatitis (NASH or fatty liver) due to contemporary lifestyle choices. This breakthrough immunotherapy has revolutionized the management of advanced liver cancer, offering a more promising approach beyond traditional oral treatments.

Dr. Ashish Kumar, a Senior Consultant from Sir Gangaram Hospital, Delhi, stressed the significance of Atezolizumab-Bevacizumab as the recommended first-line therapy for advanced liver cancer, especially for patients with preserved liver functions. In a country like India, where liver cancer's incidence remains a significant concern, this therapeutic advancement offers a beacon of hope for patients grappling with this formidable disease.

In conclusion, The study not only signifies a transformative milestone in liver cancer treatment but also underscores the critical importance of regular check-ups for patients with cirrhosis. Early detection and timely intervention with Atezolizumab-Bevacizumab immunotherapy could be pivotal in improving outcomes and enhancing the quality of life for liver cancer patients in India. This breakthrough paves the way for a more optimistic future in the battle against liver cancer.

Tags : #livercancer #AIG #livercancerawareness #radiationtherapy #tumour #immunotherapy #cancerawareness #cancerpatients #medicircle

Related Stories

14 Sep

Health Ministry signs MoU with Ministry of Social Justice & Empowerment for enhanced outreach on HIV/AIDS prevention

“As health is the responsibility of all Government departments, there is a need for a ‘sub-department of health’ in all the Ministries for health impact assessment of the policies/initiatives of these Ministries right from the conceptual stages.”

View

-Advertisements-




Trending Now

Will India’s Healthcare Budget Support a Future of Robotic Surgeries?February 22, 2025
Is the World on the Brink of Another Pandemic? Scientists Discover a New Bat VirusFebruary 22, 2025
Newcastle University Expands Academic and Research Collaborations in IndiaFebruary 21, 2025
Get Ready to #BibaUp! Kriti Sanon Unveils the Season’s Most Stylish Summer CollectionFebruary 21, 2025
A Rare Condition: Surgery Saves 2-Day-Old Baby as Organs Shift Into ChestFebruary 21, 2025
Odisha’s Bold Healthcare Vision: A Rs 12,000 Crore Blueprint for Universal Health AccessFebruary 21, 2025
Young India’s Health Crisis: Why Insurance Claims Are Rising Among 25-35 Year OldsFebruary 21, 2025
India vs. Trump’s Pharma Tariff: The Battle Over Affordable MedicineFebruary 21, 2025
Foreign Medical Aspirants in Trouble: NMC’s Warning on Pending Eligibility CertificatesFebruary 21, 2025
Think Your Work Music Helps You Focus? Science Says Think AgainFebruary 21, 2025
Is Your Home’s Air Poisoning You? Shocking New Study Reveals Hidden Indoor Pollution RisksFebruary 20, 2025
The Society of Automotive Engineers & B V Raju Institution of Technology; to host the globally prestigious E-BAJA 2025; at Hyderabad!February 20, 2025
Eat right for your heart to beat rightFebruary 19, 2025
Aakash Healthcare and Medtronic Inaugurate North India’s First Dedicated Vein ClinicFebruary 19, 2025
Urgent and accelerated HIV service delivery with equity and rights is critical to end AIDSFebruary 19, 2025
Fasting Fad or Future Health Threat? Why Teens Should Think Twice Before Intermittent Fasting February 19, 2025
Public Hospitals Go High-Tech: AIIMS Delhi Leads India’s Robotic Surgery WaveFebruary 19, 2025
Screen Time and Healthy Habits: Navigating Optimal Development in ChildrenFebruary 18, 2025
SRM Global Hospitals Launches WOW, a Centre Exclusively for Women’s Health and WellnessFebruary 18, 2025
The Hidden Dangers of Scented Candles: Aesthetic Bliss or Silent Health Hazard?February 18, 2025